Mechanistic molecular imaging of cardiac cell therapy for ischemic heart disease

Qiujun Yu, Weiwei Fan, and Feng Cao
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
Submitted 1 February 2013; accepted in final form 21 July 2013

Yu Q, Fan W, Cao F. Mechanistic molecular imaging of cardiac cell therapy for ischemic heart disease. Am J Physiol Heart Circ Physiol 305: H947–H959, 2013.—Cell-based myocardial regeneration has emerged as a promising therapeutic option for ischemic heart disease, though not yet at the level of routine clinical utility. Despite the encouraging results from initial preclinical studies that have demonstrated improved function and reduced infarct size of the ischemic myocardium following several candidate cell transplantation, the beneficial effects and molecular mechanisms of cardiac cell therapy are still unclear in clinical applications to date, and much remains to be optimized. To improve engraftment, accurate methods are required for tracking cell fate and quantifying functional outcome. In the present review, we summarized the current status and challenges of cardiac cell therapy for ischemic heart disease and discussed the strengths and limitations of currently available in vivo imaging techniques with special focus on the newly developed multimodality approaches for assessing the efficacy of engrafted donor cells. We also addressed the hurdles these imaging modalities are facing, including issues regarding immunogenicity and tumorigenicity of transplanted stem cells, and provided some the future perspectives on stem cell imaging.

molecular imaging; stem cell therapy; ischemic heart disease

This article is part of a collection on Physiological Basis of Cardiovascular Cell and Gene Therapies. Other articles appearing in this collection, as well as a full archive of all collections, can be found online at http://ajpheart.physiology.org/

Introduction

Ischemic heart disease (IHD) is the predominant contributor to cardiovascular morbidity and mortality. After myocardial infarction (MI), the limited survival of cardiac cells renders the injured heart susceptible to unfavorable remodeling and functional failure. For now, heart transplantation is the only viable treatment option for patients with end-stage heart failure. Because of the persistent shortage of donor heart organs, stem cell therapy has emerged as a promising therapeutic strategy for acute and chronic IHD. Several candidate cell types have been used in the preclinical and clinical trials for myocardial repair either directly through tissue regeneration or indirectly through paracrine action. Representative seed cells are adult stem cells (ASCs), embryonic stem cells (ESCs) (14), and induced pluripotent stem cells (iPSCs) (70). At present, the most clinically applicable cell type is ASCs, which include skeletal myoblasts (1, 51), bone marrow–derived cells (15, 49, 61), and most recently cardiac stem cells (CSCs) (43, 53).

Various cell types exhibit potential for cardiovascular repair, and numerous animal studies in recent years have shown that stem cell therapy administered after MI can improve function and limit infarction. Despite the initial encouraging results, the functional benefits are modest and inconsistent in clinical applications to date, and much remains to be optimized. Several fundamental questions remain unanswered regarding to the long-term fate of the transplanted cells. Do they survive and integrate? How can their proliferation, differentiation, and migration be controlled? What are their transcriptional and functional profiles? This review will start with a brief discussion of currently available in vivo imaging modalities which hold potential to noninvasively provide quantitative information and longitudinal assessment of cell fate. We will then focus on molecular imaging of the efficacy and safety issues regarding stem cell therapy in IHD.

Molecular Imaging for the Survival and Kinetics of Engrafted CSCs

It is a prerequisite that the transplanted stem cells reach the injury site and survive so as to function well in the target tissue. Before the advent of molecular imaging, determination of cell fate mainly relies on post mortem histological analysis, which is performed at predetermined time points following cell transplantation and requires animal death, precluding longitudinal cell tracking. Molecular imaging enables in vivo tracking of the distribution and long-term viability of stem cells by labeling cells with specific markers, including iron particles, radionuclides, and reporter genes. Labeled stem cells can be visualized noninvasively using multiple imaging modalities, such as MRI (17), single photon emission tomography (SPECT),...
Iron particle labeling. Labeling cells with iron particles for MRI visualization is one of the most frequently applied methods for cell tracking. The most commonly used iron formulation is superparamagnetic iron oxide particles because of their potent negative contrast effects and inherent lack of cell toxicity (56). The labeling of iron particles has to be completed ex vivo before transplantation, because most stem cells must be induced to take up these MRI contrast agents (28). The feasibility of tracking superparamagnetic iron oxide-labeled stem cells has been demonstrated previously in animal models of MI (33). With high spatial resolution and without ionizing radiation, MRI represents an attractive noninvasive way to produce anatomic information of highest quality for cell localization. In addition, the relatively low sensitivity has been recently demonstrated to be enhanced to single cell level using higher magnetic fields (>3 T) (85), though exposure to such high magnetic fields is not recommended in humans. However, limitations exist regarding this technique. Labels, via taken up by macrophages, could persist in the myocardium for up to 5 wk after cell death, generating false-positive signals that could be misinterpreted as robust cell survival (73). In addition, the labels may no longer be detectable once the cells divide, and MRI is contraindicated in IHD patients with implantable devices (e.g., pacemakers and defibrillators), who are often in greater need of stem cell therapy. Furthermore, despite minimal effect of iron particles on in vitro proliferative capacity and cell viability, there are recent data raising concern about the impact of chondrogenic differentiation of mesenchymal stem cells (MSCs) (40).

Radionuclide labeling. Recent improvements in spatial resolution of small animal PET and SPECT cameras have enabled the implementation of specialized systems for in vivo tracking of radionuclide-labeled cells (46). Direct radionuclide labeling of stem cells has been used to quantify the retention and biodistribution of transplanted cells in experimental and clinical studies. For example, ex vivo cell labeling with 18F-fluorodeoxy-glucose (18FDG) is mediated via glucose transporters on cell surface (27). Following uptake into cells, 18FDG is phosphorylated by hexokinase, thus trapped within the labeled cells, permitting the detection using PET. Similarly, direct cell labeling with 111indium-oxine (3) or 99mTc-hexamethylpropyleneamidine oxime (52) has been used in conjunction with SPEC, and copper-64-pyruvaldehyde-bis (N4-methylthiosemicarbazone) (2) or 18FDG (8) with PET for tracking various cell types following transplantation. When compared with MRI, PET and SPECT have significantly higher sensitivity despite a lower spatial resolution. However, a major concern of using radioactive labeling is radiation exposure (16), which may inhibit cell viability and differentiation. A recent study in a rat model of MI demonstrated significant reduced proliferation and function of 99mTc-hexamethylpropyleneamidine oxime-labeled human hematopoetic progenitor cells despite accurate homing to the infarcted myocardium (52). Another problem lies in the short half-life of the radiotracer, which may limit the duration for long-term cell tracking (a couple of hours in the case of 18FDG and a few days in the case of 111In and 64Cu). Additionally, a potential limitation is the label loss by diffusion or cell death with uptake of the label by neighboring viable cells (16).

To overcome the high toxicity of most radiopaque contrast agents, new emerging strategies have exploited microencapsulated imaging techniques that provide immunoprotection of transplanted donor cells. High concentrations of radiopaque agents can be incorporated into the microcapsule to enable visualization by X-ray fluoroscopic and computerized tomography (CT) imaging (5). Such technique can be used in combination with reporter gene transfection so as to deliver stem cells using conventional X-ray imaging platforms with follow-up examination by PET/CT or SPECT/CT.

Reporter gene labeling. Reporter genes labeling offers the possibility to circumvent the aforementioned limitations of direct radiolabeling (63). The reporter gene encodes a membrane receptor, transporter, or enzyme that is not normally expressed in the target cell and is linked to an inducible, constitutive, or tissue-specific promoter/enhancer. Therefore, the resultant reporter construct enables the enrichment of a systemically injected probe exclusively in the genetically modified cells, and more importantly, the signal is specific and dependent on the viability of the transplanted cells to maintain the transcription and translation of reporter proteins. If the cells are apoptotic or dead, they will in most cases cease to emit signals. Therefore, the imaging signal by reporter gene labeling is able to determine cell viability, preclude the risk of probe dilution or leakage following cell death, and allow monitoring of cell proliferation and long-term repeated imaging (66). Another obvious advantage of using report gene constructs is their adaptability to multiple imaging modalities. For example, fluorescent reporter proteins (e.g., monomeric red fluorescent protein, enhanced green fluorescent protein, and enhanced cyan fluorescent protein) allow imaging at the single cell level by fluorescence microscopy as well as isolation of stable cell populations by flow cytometry cell sorting. Luciferase reporters (e.g., firefly luciferase, renilla luciferase, and click beetle luciferase), on the other hand, can be used for BLI, a high-throughput and low-signal-to-noise strategy for cell tracking in small animals (22). Fluorescence and BLI, however, rely on low energy photons that become attenuated within deeper tissues. To overcome poor tissue penetration and high background signal, imaging of large animals and humans requires PET/SPECT imaging. For instance, the herpes simplex virus thymidine kinase (HSV-tk) reporter gene labeled with 124I or 18F is used for PET imaging (26, 48) (Fig. 1), and the human sodium iodide symporter (NIS) reporter gene is used for PET imaging with 124I as tracer or for SPECT imaging with 99mTc (72).

Despite the above advantages, several hurdles prevent reporter imaging from being applied in routine clinical practice. Transgene expression in the cell progeny is not guaranteed even when viral vectors are used, thus the signal will decrease when cells divide. Genetic modification may alter stem cell properties and compromise the functional benefit from cell transplantation. Transcriptional and proteomic analysis have showed changes in cell cycling, cell death, and metabolic gene expressions by reporter genes in mouse ESCs (mESCs), though no significant interference of function and differentiation was observed (82). Other issues include tissue spatial resolution, immunogenicity of reporter proteins, mutagenesis, and oncogenicity of viral vectors.
Contrast-enhanced ultrasound and three-dimensional optical imaging. Echocardiography has been traditionally used as an inexpensive and noninvasive method to evaluate cardiac structure and function in clinical practice. Molecular imaging using contrast-specific ultrasound (CEU) has recently become possible with the development of novel “site targeted” microbubbles (45). This technique relies on the ultrasonic detection of custom-designed microbubble contrast agents that are retained in area of interest via special shell composition or the conjugation of specific targeting ligands. A recent study by Kuliszewski et al. demonstrated in vivo CEU imaging of endothelial progenitor cells (EPCs) using EPC-targeted microbubbles loaded with monoclonal antibody against H-2Kk, a unique marker protein expressed by EPCs (55). The efficacy of CEU imaging of cell therapy was further confirmed by Cui et al. (20), who reported significantly increased signal from microbubble-filled MSCs than unlabeled MSCs. These studies are the first to describe CEU imaging of progenitor cells and demonstrate the potential of this technique for tracking engraftment of progenitor cells.

Recently, investigators have developed approaches that allow for three-dimensional (3-D) optical imaging. Fluorescence molecular tomography and bioluminescence tomography (BLT) collects photons that have propagated through tissue at multiple views and combines these signals tomographically to obtain the distribution of luminous source in deep tissues. Our group recently developed a dual BLT/microCT imaging system for visualizing transplanted stem cells in ischemic tissue (46). BLT with microCT coregistration can improve reconstruction accuracy and benefit 3-D volumetric data.

Multimodality molecular imaging. To combine the strengths of different imaging systems, multimodality imaging has been recently explored to monitor the kinetics of stem cells survival, proliferation, and migration in vivo. For example, we recently established a versatile imaging platform using ASCs with constitutive expression of dual-reporter gene firefly luciferase and enhanced green fluorescent protein (Fluc-eGFP), which enabled quantitative 3-D imaging of the cells’ distribution and kinetics in vivo via BLI/fluorescence imaging/BLT/micro-CT (24). Recently, Templin et al. (71) demonstrated the feasibility
of detecting $^{123}$I-labeled and NIS-transfected human-induced pluripotent stem cells (hiPSCs) in border zones of infarcted territory by using cardiac hybrid imaging (71). This new technique used 3-D NOGA mapping to guide catheter-based intramyocardial injection of NIS$^+$-hiPSCs and applied dual-isotope single photon emission computed tomographic/computed tomographic (SPECT/CT) imaging with the use of $^{123}$I SPECT to follow donor cell survival and distribution, and $^{99m}$Tc-tetrofosmin SPECT for perfusion imaging (Fig. 2). This technique was later optimized by contrast-enhanced coronary

![SPECT/CT imaging of myocardial perfusion (7 days after myocardial infarction)](image1)

![NOGA-mapping of myocardial infarction and sites of cell injection (7 days after myocardial infarction)](image2)

![SPECT/CT imaging of $^{123}$I for detection of hiPSC grafts (3 hours after pre-labeled NIS$^+$ hiPSC injection)](image3)

![Anti-VENUS](image4)

![Anti-OCT4](image5)

Fig. 2. In vivo cardiac hybrid single photon emission computed tomography/computed tomography (SPECT/CT) demonstrates successful induction of myocardial infarction (MI) and suggests long-term survival of sodium iodide symporter transgenic human-induced pluripotent stem cell (NIS$^+$-hiPSC) grafts. Representative images of a heart of 1 of 3 recipient animals that were euthanized 6 h after cell injection are shown. Line 1: SPECT/CT in vivo imaging of the left ventricle (LV) demonstrates a loss of myocardial perfusion (blue) in the anteroapical and septal walls after occlusion of the left anterior descending coronary artery. Noninfarcted myocardium appears orange colored, indicating normal $^{99m}$Tc-tetrofosmin uptake. Line 2: 3-dimensional (3-D) NOGA mapping of the LV recorded during cell injection. NOGA colors represent unipolar voltage values: red = scar and green to blue = viable tissue. Cell injection sites in the lateral [NIS$^+$-hiPSCs + mesenchymal stem cells (MSCs)], septal (NIS$^+$-hiPSCs), and anterior (nontransgenic MSCs) walls are shown as brown dots. Line 3: SPECT/CT imaging of LV 1 h after catheter-based intramyocardial cell injection demonstrating intense $^{123}$I signals (yellow) in the lateral and septal walls that correspond exactly to the injection sites (each injection area $5 \times 10^7$ hiPSCs), as recorded by NOGA mapping; control cells did not result in a detectable radiotracer signal (anterior wall). Co-administration of MSCs markedly increased signal intensity (lateral wall). Immunohistochemistry: Depicted are immunohistological sections of the lateral ventricle wall showing a cell injection channel 6 h after cell application filled with cotransplanted human MSCs (hMSCs) and Venus$^+$ NIS$^+$-hiPSCs stained for Venus and octamer-binding transcription factor 4 (OCT4; each with brown color). Reprinted with permission from Templin et al. (71).
computed tomography angiography to reveal the exact anatomic location of the injected stem cells with the corresponding perfusion defect together with the related coronary vessels (25) (Fig. 3).

Molecular Imaging the Efficacy of Donor Stem Cells

Differentiation and incorporation of stem cells. In vivo imaging offers the opportunity to answer one fundamental question whether the transplanted stem cells could effectively differentiate into cardiomyocytes and incorporate to the host environment within infarcted myocardium. To this end, reporter gene imaging modalities are most appropriate for assessing cell differentiation and incorporation, whereas direct imaging is more suitable for high-resolution detection of cell location. Cardiac-specific promoters have been used as sensors of the cell differentiation state. In this approach, α-myosin heavy chain (α-MHC) promoter driving the expression of an antibiotic resistance gene can be used for in vitro cardiomyocytes selection (37). A similar system using firefly luciferase or HSV-tk reporter gene can offer in vivo quantitative monitoring of stem cell differentiation via BLI or PET. A previous study using mESCs, which was engineered to express the enhanced cyan fluorescent protein under the control of the cardiac-specific α-actin promoter, demonstrated cardiomyocyte-directed differentiation of stem cells via enhanced cyan fluorescent protein fluorescence (7).

Previously, the integration and synchronization of differentiated stem cells with the host tissue was confirmed by positive staining for myosin regulatory light chain 2v, a specific ventricular sarcomeric protein, and the gap junction protein connexin 43. With the use of molecular imaging techniques, noninvasive tracking of acute cardiac retention and long-term survival is now feasible. A previous study using 111In-radio-tracer observed that only 4.7% of injected human EPCs were retained in the infarcted myocardium of athymic nude rats (49). Similar findings were seen in a human study using [18F]-FDG PET tracer to follow the intracoronary delivery of bone marrow cells in MI patients (83). In addition, a recent study in a rat MI model showed <0.5% of transplanted CSCs remained alive 8 wk after transplantation (44). A recent study using mechanistic...
BLI demonstrated that MSCs survived for up to 50 days, differentiated into endothelial cells, and integrated into capillary network in vivo after experimental MI (Fig. 4), and increased angiogenesis and decreased fibrosis were associated with cardiac functional improvement after MSC transplantation (78). Another study using BLI for in vivo analysis of biodistribution showed that a significant number of bone marrow mononuclear cells injected into the heart actually migrated to the femur, liver, and spleen (75).

**Paracrine action of stem cells.** Myocardial and vascular regeneration have been initially proposed as mechanisms underlying the improved cardiac function after cell therapy in MI.

---

**Fig. 4.** Mechanistic molecular imaging of hMSCs for murine MI. A: schematic representation of lentivirus, the dual reporter construct. The mCherry-Renilla luciferase (C/r-Luc) fusion reporter gene is driven by the murine stem cell virus (MSCV) constitutive promoter. The enhanced green fluorescent protein (eGFP)-firefly luciferase (G/f-Luc) fusion reporter gene is driven by the endothelial cell-specific promoter, Tie-2. The transcriptional activity of juxtaposed promoters is oppositely directed. B: representative fluorescent microscopy images illustrate the specific and constitutive expression of reporter genes in hMSCs, transduced with lentivirus. Tie-2-driven expression of G/f-Luc in hMSCs was not detected by fluorescence microscopy. Scale bars in B are 200 μm. C: in vitro assessment of BLI signal in mouse endothelial cells (mETCs; positive control) and hMSCs is shown 72 h after lentivirus transduction. The BLI signal is detected in transduced mETCs with coelenterazine (CLTZ) and D-luciferin (D-Luc), indicating expression of both Tie-2-driven r-Luc and constitutive f-Luc. In contrast, only r-Luc-induced BLI signal is detected in transduced hMSCs. Quantification of the BLI signals (photons/s) is illustrated as a bar graph (bottom). D: BLI of graded numbers of hMSCs 48 h after lentivirus transduction was performed to correlate signal intensity and cell number. Quantification of BLI signal intensity shows a robust correlation between r-Luc and c-Luc. Quantification of transduced hMSCs (bottom). E: representative photographs and quantification of the BLI signals in the hearts of a representative SCID mouse for the indicated time point after injection of hMSCs/medium after acute MI. The signals were probed by intraperitoneal injection of CLTZ (top) or of D-Luc (bottom). BLI intensity was assessed by measuring the photon flux from the region of interest drawn over the precordium. *P < 0.05 and **P < 0.01; n = 6 mice/group. F: immunostaining for CD31 and GFP showed the presence of endothelial-differentiated hMSCs (GFP++) in the vessels of the border zone at 2 wk after hMSC injection. Scale bar is 200 μm. Reprinted with permission from Wang et al. (78).
However, in many cases, the number of differentiated cardiomyocytes and vascular cells derived from transplanted stem cells, especially the ASCs, appears too small to account for the observed significant cardiac improvement. Thus the prevailing concept of stem cell efficacy has shifted toward an alternative hypothesis, the “paracrine mechanism,” according to which the transplanted cells are proposed to release soluble factors that contribute to cardiac repair and regeneration (30). This notion is further supported by studies showing that the administration of conditioned medium is able to recapitulate, at least partly, the beneficial effects of stem cell therapy (29). Indeed, various implanted stem cells, including skeletal myoblasts (59), bone-marrow-derived cells (39, 50), and cardiac-derived cell (18), have demonstrated the ability to produce and secrete a wide range of cytokines, chemokines, and growth factors that are known to be involved in cardiac repair.

The paracrine factors may influence adjacent cells and exert their actions via several mechanisms. They can induce cytoprotection of resident myocytes, mediate neovascularization, modulate the postinfarction inflammatory and fibrogenic processes, and stimulate endogenous regeneration and recruitment of endogenous stem cells (19, 30). Furthermore, it is noteworthy that the production of these paracrine factors could be further increased by ischemic insult (36). Under hypoxic stress in ischemic myocardium, the vascular endothelial growth factor (VEGF), basic fibroblast growth factor, hepatocyte growth factor, hypoxia inducible factor-1, and stromal cell-derived factor-1 are significantly increased in injured hearts treated with MSCs or multipotent stromal cells (30). With multimodality BLI/microCT imaging, we recently demonstrated multipotent adipose stromal cells therapy promoted recovery from hindlimb ischemia through enhancing proangiogenic signal in vivo, though the cells failed to incorporate into the host microvasculature as functional components (24). Using in vivo BLI, a recent study reported that porcine PSC-derived endothelial cells could also improve cardiac function after MI via release of proangiogenic and antiapoptotic factors in the ischemic microenvironment (31) (Fig. 5). Thus the paracrine hypothesis extends the traditional concept to include the influence of stem cell released factors on the post-MI microenvironment and rationalizes the persistence of benefit despite the poor survival of transplanted cell.

As the survival of transplanted stem cell is challenged by hypoxia, inflammation, and anokis, it is necessary to enhance the cell resistance to ischemic niche for promoting the paracrine or differentiation potential of donor cells (79). The current strategies include pharmacological pre-/postconditioning, genetic modification, combined cell transplantation, and biomaterial engineering (81). Using BLI, a recent study from our group demonstrated that rosuvastatin could improve the survival of engrafted multipotent adipose stromal cells in infarcted myocardium involving phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 signaling pathways, which significantly promoted post-MI function (Fig. 6). The emerging epigenetics and posttranscription processing strategies potentiate the DNA-free modification of stem cells, which may promote the efficacy of cell-based IHD therapy to translate in to clinical setting. Moreover, biochemical engineering tools can also be designed to promote the survival and paracrine manner (e.g., growth factors) of engrafted stem cells (21, 80). For example, our latest efforts have been focused on the synthesis of a multifunctional VEGF-loaded IR800-conjugated nanocarrier, which targets VEGF receptors and maintains an elevated level of VEGF in ischemic tissues for a prolonged time (67). The dynamic accumulation of these nanocarriers in the ischemic muscle and the resultant increase in blood perfusion, oxygen saturation, and angiogenesis could be monitored by multimodality imaging, combining fluorescence imaging, laser Doppler, photoacoustic imaging, and 18F-alffatide PET imaging.

**Functional outcomes of ischemic myocardium.** The goal of stem cell therapy is to replace injured tissue with new cells to restore heart function. Thus precise evaluation of the functional outcome of cell therapy is of primary importance. Clinical studies as well as animal studies have mainly focused on detection of differences in left ventricular (LV) function, infarct size, myocardial perfusion, and myocardial viability, and these parameters can be achieved noninvasively by various imaging modalities, including echocardiography, MRI, CT, and nuclear techniques.

For LV size and systolic function measurement, the most accurate assessment is contrast-enhanced MRI, which is often selected over echocardiography because of its high spatial resolution, whereas CT and PET/SPECT are not preferred because of their lower temporal resolution and exposure to radiation. Previous clinical trials, which investigated the cardiac benefit of adult progenitor cell therapy in acute MI and chronic IHD, have shown increase in LV ejection fraction varying from 3 to 18% (6). The most preferred technique for infarct size measurement is again MRI, which allows precise detection of infarction and currently the only technique discriminating between subendocardial and transmural infarction (77). Reduction in infarct size has been reported in patients undergoing cell therapy; however, control patients have also exhibited a comparable reduction in infarct size (54). Therefore, randomized controlled trials are needed to evaluate changes in infarct size after cell therapy compared with the natural evolution after reperfusion.

Most of the currently available studies used SPECT for evaluating myocardial perfusion and have shown a decrease in myocardial perfusion defect size after adult progenitor cells therapy, suggesting increased growth of new small vasculature after stem cell engraftment (6). Only Janssens et al. (35) used PET to evaluate the effect of cell therapy on perfusion and failed to observe increased myocardial perfusion. It should be emphasized that only PET permits absolute quantification of myocardial perfusion, whereas SPECT provides information on relative changes in tracer uptake. Therefore, future investigation with the use of PET is guaranteed to assess both rest and stress perfusion in patients receiving stem cell therapy. In addition, coronary blood flow can be invasively assessed using Doppler flow wire at rest and during pharmacological stress. Subsequent calculation of the coronary flow reserve provides insight into the integrity of both the epicardial conduit arteries and the distal microvascular bed.

The final measure of functional outcome is myocardial viability, which can be assessed by either nuclear imaging with PET (mainly using 18F-FDG) and SPECT (using 18F-FDG or 99mTc-labeled agents) to evaluate glucose utilization or low-dose dobutamine echocardiography and MRI to assess contractile reserve. We have previously performed a 4-yr follow-up study evaluating the safety and efficacy of intracoronary delivery of autologous bone marrow mononuclear cells in...
patients with ST-elevated MI who received PCI and found no significant improvement in myocardial viability of the infarcted area assessed by SPECT, though overall LV function increased (13, 65). Clinical studies using nuclear imaging techniques have shown increased tracer uptake ranging from 15–55% posttherapy with adult progenitor cells (23, 64). Contractile reserve as measured by echocardiography, however, has not shown significant enhancement (84). Additional studies, evaluating different features of viable myocardium in the same patients, are needed to elucidate changes in myocardial viability after cell therapy. In addition, nonfluoroscopic catheter-based electromechanical mapping enables identification and localization of viable myocardial tissue by simultaneous assessment of electrical activation and local mechanical response.

**Molecular Imaging in Safety Issue of Stem Cells**

Unlike ASCs that are generally limited by their plasticity, the capacity of ESCs and iPSCs to differentiate into almost all...
human cell types highlights their promising role in regenerative therapy for IHD. However, there are several critical issues unresolved before clinical translation. Two major concerns are the ability of undifferentiated ESCs and iPSCs to form teratomas and the possibility to trigger host immune response after allogeneical transplantation. Therefore, it is imperative to develop noninvasive imaging modalities that allow for longitudinal, repetitive, and quantitative assessment of transplanted cell survival, proliferation, and migration in vivo, which enable early detection of teratoma formation and immunological rejection.

**Imaging of immunogenicity of transplanted stem cells.** Although the ESCs was initially expected to possess “immune privilege” for low expression of MHC-I and no MHC-II, previous studies showed that transplanted ESCs could trigger intense host immunologic rejection (62). This immunogenicity will further increase upon ESCs differentiation and teratoma formation. This notion is supported by a study using murine model of MI which demonstrated intragraft infiltration of inflammatory cells following allogeneic injection of undifferentiated mESCs and accelerated immune response against ESCs that had differentiated in vivo for 2 wk (69). Not only are
ESCs immunogenic, even iPSCs (87) and MSCs (60) that are previously believed to express lower levels of alloantigens and other costimulatory molecules have been recently reported to be visible to the recipient’s immune system. However, the immunogenicity of iPSc is still controversial, as a latest study suggested limited immunogenicity of transplanted cells differentiated from iPSCs and ESCs (4). Therefore, the immunogenicity of different donor cell types for IHD treatment should be rigorously investigated in preclinical studies.

Monitoring cell viability is a critical requirement to assess immunogenicity, as a provoked immune reaction can kill transplanted cells. In small animals, molecular imaging has not only been used to confirm the fact that stem cell rejection occurs in immunocompetent recipients but has also provided insight into therapeutic strategies to prevent rejection (possible strategies to minimize rejection of stem cell transplants have been extensively reviewed elsewhere (9)). One study used BLI to show that transplanted xenogeneic human ESCs (hESCs) in immunocompetent mice survived only 7 to 10 days after primary injection and only 3 days after repeat transplantation (68). And another study used BLI to demonstrate that short-term immunosuppression with leukocyte costimulatory blockade agents allowed long-term engraftment of xenogeneic cells (58).

**Imaging of tumorigenicity of transplanted stem cells.** Although the pluripotent character of ESCs and iPSCs make them extremely suitable for regeneration therapy, they can also exert unintended tumorigenic adverse effects. We have previously observed the formation of intracardiac and extracardiac teratoma 4 wk after injection of mESCs into the myocardium of adult nude rats (12), suggesting a major hurdle that we have to overcome before taking pluripotent cells from bench to bedside for myocardial repair.

Although it is not fully understood now how teratoma formation occurs within differentiated ESC- or iPSC-derived cell lines, it is believed that the presence of remnant, undifferentiated cells present within the transplanted cell population may, at least in part, contribute to teratoma formation. The molecular basis of the tumorigenicity of pluripotent cells lies in their cancer-resembling properties, including self-renewal, rapid proliferation, lack of contact inhibition, and telomerase activity, which are promoted by several molecular processes and have been described in detail elsewhere (38). Clear insights into the gene expression of pluripotent cells will allow researchers to select a pluripotent cell population with a reduced tumorigenic signature. It should be noted that no selection method is available at present to yield 100% pure cell population, which is a major obstacle for in vitro manipulation of ESCs and iPSCs. Interestingly, transplantation of selected hESC-derived cells in a more developed phase into immunosuppressed rats did not result in teratoma formation, even when this population is not 100% pure (82.6 ± 6.6%, range 71–95%) (41). Nevertheless, intracardiac injection of undifferentiated mESCs leads to teratoma formation inevitably in all recipients after only 3 to 4 wk (12, 57). Clinical translation of pluripotent cells will therefore partly depend on the ability to purify the cell population and to detect teratoma formation early. Non-genetic method using a mitochondria fluorescent dye, tetramethylrhodamine methyl ester perchlorate selectively, has been recently reported to selectively mark iPSC-derived cardiomyocytes, and purify cardiomyocyte by fluorescence-activated cell sorting (32). Biochemical differences in glucose and lactate metabolism between cardiomyocytes and noncardiomyocytes, including undifferentiated cells also enabled mass production of iPSC-derived cardiomyocytes (74). Both methods obtained cardiomyocytes of up to 99% purity that did not form tumors after transplantation.

Tumor detection can be achieved by several non-invasive imaging modalities to track the survival and proliferation of pluripotent cells in vivo. The most commonly used technique BLI using Fluc. BLI is easy to use and very sensitive to detect teratoma formation even before a palpable tumor is formed (42, 76). It has been shown that no teratoma formation is observed following intramyocardial injection of a maximum of $1 \times 10^4$ undifferentiated hESCs into immunodeficient mice (42). These findings provided important preclinical insights into the effects of hESC numbers and local niches on teratoma development as well as the kinetics of teratoma formation.

However, BLI is not suited for clinical application because of its limited penetration of the signal through tissue in larger animals, and the lack of spatial resolution. In contrast, MRI and PET are superior but have significantly lower detection threshold. Therefore, the use of multimodality imaging may provide a better solution. We have tested BLI combined with PET imaging to monitor transplanted ESC survival and proliferation in vivo and assess the efficacy of suicide gene therapy as a backup safety measure against teratoma formation (10). In specific, teratoma ablation was achieved via a reporter-suicide gene construct. mESCs were stably transduced with a triple-fusion reporter gene that consisted of monomeric red fluorescent protein, Fluc and herpes simplex virus truncated thymidine kinase transplanted into adult nude mice. BLI and PET imaging were performed using 6- luciferin and 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine reporter probes, respectively. ESCs were completely ablated by Ganciclovir treatment 3 wk after transplantation.

Although this study showed ablation of teratomas formed from ESCs, the construct is still based on genetically modifying the pluripotent cells by viral transduction, which has tumorigenic potential as well. Future approaches therefore should focus on site-specific genomic integration approaches such as zinc finger nuclease (34) or phiC31 integrase (47) to minimize potential adverse effects to the cells. Alternatively, one could bypass the reporter gene technique by designing molecular probes that target cell surface receptors of teratoma, as was recently demonstrated using $^{64}$Cu-labeled RGD tetramer that targets $\alpha_v\beta_3$ integrin receptors on hESC-derived teratomas (11).

**Conclusion and Future Perspectives**

Imaging cell fate after transplantation is a high priority in both basic research and clinical translation. For cell-based therapy to truly succeed, we must be able to track the locations of delivered cells, the duration of cell survival, and any potential adverse effects. The ideal imaging platform should be biocompatible, safe, and nontoxic; noninvasive in living subjects; capable of detecting single cell and quantifying cell number; and have no dilution with cell proliferation. The advances in the field of molecular imaging hold promise for answering various questions about the optimal cell types, cell dosage, timing of administration, as well as cell location and...
viability over time. Future efforts should continue focusing on 1) labeling cells without adverse effects on cellular function, 2) tracking them in vivo with high sensitivity, spatial resolution, and over long periods of time without loss of signal; 3) demonstrating differentiation of cardiomyocytes function in a normal physiological way in vivo, and 4) targeting cells upon tumor formation and preventing immunological rejection. These goals are laden with obstacles that will ultimately require integration of molecular biology, cell biology, immunology, tissue engineering, transplantation biology, and clinical expertise. The development of multimodality imaging approaches will pave the way for safe myocardial regeneration in IHD.

GRANTS
This work was supported by National Basic Research Program of China 2012CB518101; National Nature Science Foundation of China Grants 81270168, 81090274, and 81090270; Feng Cao Grant BWS12J037; Innovation Team Development Grant by China Department of Education Grants 81270168, 81090274, and 81090270; Feng Cao Grant BWS12J037; GRANTS

AUTHOR CONTRIBUTIONS
Q.Y. and W.F. prepared figures; Q.Y. and F.C. approved final version of manuscript; F.C. edited and revised manuscript; Q.Y., W.F., and F.C. approved final version of manuscript; F.C. conception and design of research.

REFERENCES
MECHANISTIC MOLECULAR IMAGING OF CARDIAC CELL THERAPY

Review

H958


